ABSTRACT
About 70% of breast tumors express estrogen receptor alpha (ERα), which mediates the proliferative effects of estrogens on breast epithelial cells, and are candidates for treatment with antiestrogens, steroidal or non-steroidal molecules designed to compete with estrogens and antagonize ERs. The variable patterns of activity of antiestrogens (AEs) in estrogen target tissues and the lack of systematic cross-resistance between different types of molecules have provided evidence for different mechanisms of action. AEs are typically classified as selective estrogen receptor modulators (SERMs), which display tissue-specific partial agonist activity (e.g. tamoxifen and raloxifene), or as pure AEs (e.g. fulvestrant), which enhance ERα post-translational modification by ubiquitin-like molecules and accelerate its proteasomal degradation. Characterization of second- and third-generation AEs, however, suggests the induction of diverse ERα structural conformations, resulting in variable degrees of receptor downregulation and different patterns of systemic properties in animal models and in the clinic.
Subject(s)
Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacology , Animals , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Clinical Trials as Topic , Drug Evaluation, Preclinical , Drug Resistance, Neoplasm , Estrogen Antagonists/therapeutic use , Estrogen Receptor alpha/antagonists & inhibitors , Estrogen Receptor alpha/chemistry , Estrogen Receptor alpha/metabolism , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic/drug effects , Humans , Models, Molecular , Molecular Conformation , Molecular Structure , Mutation , Protein Binding , Protein Processing, Post-Translational , Receptors, Estrogen/antagonists & inhibitors , Receptors, Estrogen/chemistry , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Selective Estrogen Receptor Modulators/chemistry , Selective Estrogen Receptor Modulators/pharmacology , Selective Estrogen Receptor Modulators/therapeutic use , Structure-Activity Relationship , Treatment OutcomeABSTRACT
Autism spectrum disorder (ASD) occurs in 1 in 68 births, preferentially affecting males. It encompasses a group of neurodevelopmental abnormalities characterized by impaired social interaction and communication, stereotypic behaviors and motor dysfunction. Although recent advances implicate maternal brain-reactive antibodies in a causative role in ASD, a definitive assessment of their pathogenic potential requires cloning of such antibodies. Here, we describe the isolation and characterization of monoclonal brain-reactive antibodies from blood of women with brain-reactive serology and a child with ASD. We further demonstrate that male but not female mice exposed in utero to the C6 monoclonal antibody, binding to contactin-associated protein-like 2 (Caspr2), display abnormal cortical development, decreased dendritic complexity of excitatory neurons and reduced numbers of inhibitory neurons in the hippocampus, as well as impairments in sociability, flexible learning and repetitive behavior. Anti-Caspr2 antibodies are frequent in women with brain-reactive serology and a child with ASD. Together these studies provide a methodology for obtaining monclonal brain-reactive antibodies from blood B cells, demonstrate that ASD can result from in utero exposure to maternal brain-reactive antibodies of single specificity and point toward the exciting possibility of prognostic and protective strategies.
Subject(s)
Membrane Proteins/genetics , Membrane Proteins/metabolism , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Adult , Animals , Antibodies/blood , Antibodies/metabolism , Autism Spectrum Disorder/etiology , Autism Spectrum Disorder/genetics , Autistic Disorder/genetics , Autistic Disorder/metabolism , Brain/metabolism , Complement C6 , Female , Hippocampus/metabolism , Humans , Learning , Maternal-Fetal Exchange , Membrane Proteins/blood , Mice , Mice, Inbred C57BL , Middle Aged , Mothers , Nerve Tissue Proteins/blood , Neurons/metabolism , Pregnancy , Prenatal Exposure Delayed Effects/metabolism , Sex Factors , Social BehaviorABSTRACT
BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibodies have been recently described in children with acute disseminating encephalomyelitis (ADEM), but the clinical and neuroradiological characterisation of this subgroup is lacking. OBJECTIVE: To compare the clinical and neuroradiological features of paediatric ADEM with and without MOG antibodies. METHODS: Clinical course, cerebrospinal fluid (CSF)-, MRI studies, outcome and MOG status of 33 paediatric ADEM prospectively studied were reviewed. RESULTS: MOG antibodies (median 1:2560; range 1:160-1:20â 480) were detected in 19 children with ADEM. The majority of children showed a decline of serum MOG-IgG titres over time. Children with MOG antibodies did not differ in their age at presentation, sex ratio, the presence of oligoclonal bands, clinical symptoms or initial severity, apart from a higher CSF cell count (p=0.038), compared with children without MOG antibodies. In addition, further relapsing demyelinating episodes associated with MOG antibodies were observed only in children with MOG antibodies. All 19 children with MOG antibodies had a uniform MRI pattern, characterised by large, hazy and bilateral lesions and the absence of atypical MRI features (eg, mainly small lesions, well-defined lesions), which was significantly different compared to that of children without MOG antibodies (p=0.003; and p=0.032, respectively). In addition, children with MOG antibodies had involvement of more anatomical areas (p=0.035) including the myelon characterised by a longitudinally extensive transverse myelitis (p=0.003), more often a complete resolution of lesions (p=0.036) and a better outcome (p=0.038). CONCLUSIONS: Patients with ADEM with MOG antibodies in our cohort had a uniform MRI characterised by large, bilateral and widespread lesions with an increased frequency of longitudinal extensive transverse myelitis and a favourable clinical outcome in contrast to children lacking MOG antibodies.
Subject(s)
Autoantibodies/blood , Encephalomyelitis, Acute Disseminated/diagnosis , Encephalomyelitis, Acute Disseminated/immunology , Magnetic Resonance Imaging , Myelin-Oligodendrocyte Glycoprotein/immunology , Adolescent , Brain/immunology , Brain/pathology , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Immunoglobulin G/blood , Male , Multiple Sclerosis/diagnosis , Multiple Sclerosis/immunology , Myelitis, Transverse/diagnosis , Myelitis, Transverse/immunology , Neuromyelitis Optica/diagnosis , Neuromyelitis Optica/immunology , Prognosis , Prospective Studies , Spinal Cord/immunology , Spinal Cord/pathologyABSTRACT
Autoimmune diseases currently affect 5-7% of the world's population; in most diseases there are circulating autoantibodies. Brain-reactive antibodies are present in approximately 2-3% of the general population but do not usually contribute to brain pathology. These antibodies penetrate brain tissue only early in development or under pathologic conditions. This restriction on their pathogenicity and the lack of correlation between serum titers and brain pathology have, no doubt, contributed to a delayed appreciation of the contribution of autoantibodies in diseases of the central nervous system. Nonetheless, it is increasingly clear that antibodies can cause damage in the brain and likely initiate or aggravate multiple neurologic conditions; brain-reactive antibodies contribute to symptomatology in autoimmune disease, infectious disease, and malignancy.
Subject(s)
Autoantibodies/metabolism , Brain/immunology , Brain/pathology , Hypoxia-Ischemia, Brain/immunology , Hypoxia-Ischemia, Brain/pathology , Animals , Antigen-Antibody Reactions/immunology , Brain/metabolism , Cells, Cultured , Disease Models, Animal , Humans , Hypoxia-Ischemia, Brain/metabolism , Lymphocytes/immunology , Lymphocytes/metabolism , Lymphocytes/pathologyABSTRACT
BACKGROUND: Recently we showed that antibodies to myelin oligodendrocyte glycoprotein (MOG) can be found in aquaporin-4 (AQP4)-immunoglobulin (IgG) seronegative pediatric and adult patients with definite and high-risk neuromyelitis optica (NMO). OBJECTIVE: The purpose of this study was to describe the clinical characteristics and temporal dynamics of MOG-IgG in AQP4-IgG seronegative pediatric patients presenting with definite NMO. METHODS: Children with definite NMO who were referred for further testing of serum antibodies for AQP4 and MOG with a cell-based assay were included in this study. Clinical disease course, cerebrospinal fluid and magnetic resonance imaging (MRI) studies of these patients were reviewed. RESULTS: Between 2008 and 2012 eight children who fulfilled the diagnostic criteria of definite NMO were recruited. Two children with definite NMO tested positive for AQP4-IgG but were negative for MOG-IgG antibodies. Three children had an absence of AQP4-IgG and MOG-IgG antibodies. Three children with definite NMO had high titers of serum MOG-IgG antibodies (≥1: 160), but no AQP4-directed humoral immune response. Longitudinal analysis of serum samples of the latter three children showed persisting high MOG-IgG titers over time. CONCLUSION: Pediatric patients presenting with clinical symptoms and MRI findings highly suggestive of NMO but with high and persisting MOG-IgG antibody titers are most likely to represent a distinct subgroup of acute demyelinating diseases with important clinical and therapeutic implications.
Subject(s)
Autoantibodies/blood , Myelin-Oligodendrocyte Glycoprotein/immunology , Neuromyelitis Optica/blood , Neuromyelitis Optica/immunology , Adolescent , Adult , Aquaporin 4/immunology , Autoantibodies/immunology , Autoantigens/immunology , Child , Female , Humans , Immunoglobulin G/immunology , Magnetic Resonance Imaging , MaleABSTRACT
BACKGROUND: Although arthralgia is a known adverse effect of aromatase inhibitor (ai) treatment in postmenopausal breast cancer patients, few studies have carried out a comprehensive evaluation of the nature, onset, and incidence of musculoskeletal (msk) pain in these patients. We therefore used a pilot study to identify conditions or markers predictive of pain. METHODS: For 24 weeks, we monitored 30 eligible postmenopausal women starting ai therapy. Pre-existing and incident msk conditions and pain were assessed clinically and with ultrasonography of the hands and wrists. In addition, patient questionnaires were used to assess pain before and during ai therapy. Biochemical markers were measured at baseline and at regular intervals after anastrozole therapy began. Gene profiling studies were carried out before and 48 hours after the initial ai administration. RESULTS: Over the 24-week study period, 20 participants (67%) showed no pain symptoms; 5 (17%) experienced low or moderate pain at baseline, which did not increase with ai treatment; and during therapy, 5 (17%) showed exacerbation of pain attributable to osteoarthritis of the hand and to finger flexor tenosynovitis. Although all 30 participants had some degree of msk conditions before anastrozole therapy started, the pre-existing conditions did not necessarily predispose the women to increased pain during anastrozole treatment. Higher levels of urinary N-telopeptides of type i collagen were associated with the groups presenting pain, suggesting a higher extent of pre-existing bone resorption, without significant evolution over the 24-week treatment period. Slightly higher levels of 1,25(OH)(2) vitamin D(3) were observed at baseline in patients with pain increase, but did not significantly change during treatment; however, average levels of 25(OH) vitamin D(3) increased, likely because of supplementation. Although biochemical markers did not discriminate efficiently between pain groups, a signature of 166 genes in peripheral blood mononuclear cells was identified that could stratify patients into the various groups observed in this pilot study. The gene signature was enriched in components of inflammatory signalling and chemokine expression, of antitumoural immunity pathways, and of metabolic response to hormones and xenobiotics, although no clinically significant association could be made in the present study, considering the small number of patients. Nevertheless, the observed trend suggests the feasibility of developing surrogate predictive markers of msk pain. Patient compliance was high in this study and was not affected by pain exacerbation. CONCLUSIONS: Baseline msk assessment showed pre-existing causes for pain in most of the study patients before initiation of the ai. Exacerbation of existing osteoarthritis pain and tenosynovial symptoms was the primary cause of pain increase. Musculoskeletal pain assessment at baseline and prompt treatment of pain symptoms may help to optimize adherence to ai therapy. The value of routinely assessing inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate was not supported by our pilot study. Gene expression profiles in peripheral blood mononuclear cells may be further explored in larger-scale studies as stratification markers to identify patients at risk of developing arthralgia.
ABSTRACT
Arsenic trioxide (As(2)O(3)) is an effective treatment for acute promyelocytic leukemia (APL), but is less effective against other leukemias. Although the response of APL cells to As(2)O(3) has been linked to degradation of the PML/RARalpha fusion oncoprotein, there is evidence that PML/RARalpha expression is not the only mediator of arsenic sensitivity. Indeed, we found that exogenous expression of PML/RARalpha did not sensitize a non-APL leukemic line to As(2)O(3). To evaluate possible other determinants of sensitivity of leukemic cells to As(2)O(3), we derived two arsenic-resistant NB4 subclones. Despite being approximately 10-fold more resistant to arsenic than their parental cell line, PML/RARalpha protein was still degraded by As(2)O(3) in these cells, providing further evidence that loss of expression of the oncoprotein does not confer arsenic sensitivity. Both arsenic-resistant clones contained high glutathione (GSH) levels, however, and we found that GSH depletion coupled with As(2)O(3) treatment dramatically inhibited their growth. Annexin V-staining and TUNEL analysis confirmed a synergistic induction of apoptosis. In addition, these cells failed to accumulate ROS in response to arsenic treatment, in contrast to their arsenic-sensitive parental cells, unless cotreated with buthionine sulfoximine. While other malignant cells did not show a good correlation between arsenic sensitivity and GSH content, GSH depletion nevertheless sensitized all cell lines examined, regardless of their initial response to arsenic alone. These findings suggest that PML/RARalpha expression is not a determinant of arsenic sensitivity, and further support the coupling of GSH depletion and arsenic treatment as a novel treatment for human malignancies that are unresponsive to arsenic alone.
Subject(s)
Antineoplastic Agents/therapeutic use , Arsenicals/therapeutic use , Drug Resistance, Neoplasm , Glutathione/deficiency , Leukemia, Promyelocytic, Acute/drug therapy , Oxides/therapeutic use , Annexin A5/metabolism , Antimetabolites, Antineoplastic/pharmacology , Apoptosis/drug effects , Arsenic Trioxide , Buthionine Sulfoximine/pharmacology , Cell Division/drug effects , Electrophoretic Mobility Shift Assay , Glutathione/metabolism , Humans , In Situ Nick-End Labeling , Leukemia, Promyelocytic, Acute/metabolism , Neoplasm Proteins/metabolism , Oncogene Proteins, Fusion/metabolism , Reactive Oxygen Species/metabolism , Tumor Cells, CulturedABSTRACT
We have characterized a novel mutation of the human AR, G577R, associated with partial androgen insensitivity syndrome. G577 is the first amino acid of the P box, a region crucial for the selectivity of receptor/DNA interaction. Although the equivalent amino acid in the GR (also Gly) is not involved in DNA interaction, the residue at the same position in the ER (Glu) interacts with the two central base pairs in the PuGGTCA motif. Using a panel of 16 palindromic probes that differ in these base pairs (PuGNNCA) in gel shift experiments with either the AR DNA-binding domain or the full length receptor, we observed that the G577R mutation does not induce binding to probes that are not recognized by the wild-type AR. However, binding to the four PuGNACA elements recognized by the wild-type AR was affected to different degrees, resulting in an altered selectivity of DNA response element recognition. In particular, AR-G577R did not interact with PuGGACA palindromes. Modeling of the complex between mutant AR and PuGNACA motifs indicates that the destabilizing effect of the mutation is attributable to a steric clash between the C beta of Arg at position 1 of the P box and the methyl group of the second thymine residue in the TGTTCPy arm of the palindrome. In addition, the Arg side chain can interact with G or T at the next position (PuGCACA and PuGAACA elements, respectively). The presence of C is not favorable, however, because of incompatible charges, abrogating binding to the PuGGACA element. Transactivation of several natural or synthetic promoters containing PuGGACA motifs was drastically reduced by the G577R mutation. These data suggest that androgen target genes may be differentially affected by the G577R mutation, the first natural mutation characterized that alters the selectivity of the AR/DNA interaction. This type of mutation may thus contribute to the diversity of phenotypes associated with partial androgen insensitivity syndrome.
Subject(s)
Androgen-Insensitivity Syndrome/genetics , DNA/metabolism , Mutation , Receptors, Androgen/genetics , Amino Acid Sequence , Androgens/metabolism , Animals , Base Pairing , Base Sequence , Binding Sites , Biopsy , COS Cells , Cells, Cultured , Consensus Sequence , DNA Probes , Fibroblasts/chemistry , Genitalia/pathology , HeLa Cells , Humans , Immunoblotting , Kinetics , Male , Models, Molecular , Molecular Sequence Data , Molecular Structure , Polymerase Chain Reaction , Receptors, Androgen/chemistry , Response Elements , Skin/pathology , Transcriptional Activation , TransfectionABSTRACT
Prostaglandins (PGs) generated by the enzyme cyclooxygenase (COX) have been implicated in the pathological renal hemodynamics and structural alterations in diabetes mellitus, but the role of individual COX isoenzymes in diabetic nephropathy remains unknown. We explored COX-1 and COX-2 expression and hemodynamic responses to the COX-1 inhibitor valeryl salicylate (VS) or the COX-2 inhibitor NS398 in moderately hyperglycemic, streptozotocin-diabetic (D) and control (C) rats. Immunoreactive COX-2 was increased in D rats compared with C rats and normalized by improved glycemic control. Acute systemic administration of NS398 induced no significant changes in mean arterial pressure and renal plasma flow in either C or D rats but reduced glomerular filtration rate in D rats, resulting in a decrease in filtration fraction. VS had no effect on renal hemodynamics in D rats. Both inhibitors decreased urinary excretion of PGE(2). However, only NS398 reduced excretion of thromboxane A(2). In conclusion, we documented an increase in renal cortical COX-2 protein expression associated with a different renal hemodynamic response to selective systemic COX-2 inhibition in D as compared with C animals, indicating a role of COX-2-derived PG in pathological renal hemodynamic changes in diabetes.
Subject(s)
Diabetes Mellitus, Experimental/enzymology , Isoenzymes/physiology , Kidney/enzymology , Prostaglandin-Endoperoxide Synthases/physiology , Animals , Cyclooxygenase 1 , Cyclooxygenase 2 , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Experimental/physiopathology , Dinoprostone/urine , Hemodynamics , Immunoenzyme Techniques , Isoenzymes/antagonists & inhibitors , Isoenzymes/biosynthesis , Kidney/pathology , Kidney/physiopathology , Kidney Cortex/enzymology , Kidney Cortex/pathology , Male , Membrane Proteins , Prostaglandin-Endoperoxide Synthases/biosynthesis , Rats , Rats, Sprague-Dawley , Thromboxane B2/urineABSTRACT
1alpha,25-Dihydroxyvitamin D(3) [1,25(OH)2D3] inhibits growth of cells derived from a variety of tumors in vitro and in vivo. Proliferation in vitro of human SCC25 cells, derived from a primary squamous cell carcinoma (SCC) of the tongue, was blocked by 1,25(OH)2D3 and its analog EB1089. A similar effect was observed with 13-cis retinoic acid (RA), which has been used in chemoprevention of SCC. We identified amphiregulin, a member of the epidermal growth factor family, as a 1,25(OH)2D3 target gene in SCC25 cells. Induction of amphiregulin mRNA by 1,25(OH)2D3 was rapid and sustained over 48 h, and was unaffected by cycloheximide. 1,25(OH)2D3 also induced amphiregulin mRNA in estrogen receptor-positive and -negative human breast cancer cell lines, but not in LNCaP human prostate cancer cells. RAR- or RXR-specific retinoids did not affect amphiregulin mRNA levels in SCC25 cells; however, 13-cis RA partially blocked the response to 1,25(OH)2D3. Amphiregulin partially inhibited growth of SCC25 cells in culture. Our data show that amphiregulin is a 1,25(OH)2D3 target gene, and suggest that its induction may contribute to the growth inhibitory effects of 1,25(OH)2D3.
Subject(s)
Breast Neoplasms/genetics , Calcitriol/analogs & derivatives , Carcinoma, Squamous Cell/genetics , Cholecalciferol/pharmacology , Glycoproteins/genetics , Growth Substances/genetics , Intercellular Signaling Peptides and Proteins , Amphiregulin , Antineoplastic Agents/pharmacology , Breast Neoplasms/pathology , Breast Neoplasms/prevention & control , Calcitriol/pharmacology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/prevention & control , Cell Division/drug effects , Dose-Response Relationship, Drug , EGF Family of Proteins , Gene Expression Regulation, Neoplastic/drug effects , Humans , Isotretinoin/pharmacology , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tumor Cells, CulturedABSTRACT
The age-related decline in beta-adrenergic receptor (beta-AR)-mediated vasorelaxation is associated with desensitization of beta-ARs without significant downregulation. The primary mode of this homologous beta-AR desensitization, in general, is via G protein receptor kinases (GRK). Therefore, we hypothesize that age-related changes in GRKs are causative to this etiology in rat aorta. Herein, we investigate the activity and cellular distribution (cytoplasmic vs. membrane) of several GRK isoforms and beta-arrestin proteins. GRK activity was assessed in extracts from aortic tissue of 6-wk, 6-mo, 12-mo, and 24-mo-old male Fischer-344 rats using a rhodopsin phosphorylation assay. We also performed immunoblots on lysates from aorta with specific antibodies to GRK-2, -3, -5, and beta-arrestin-1. Results show an age-related increase in GRK activity. Furthermore, expression of GRK-2 (cytoplasmic and membrane), GRK-3 (cytoplasmic and membrane), and beta-arrestin (soluble) increased with advancing age, whereas GRK-5 (membrane) expression remained unchanged. These results suggest that age is associated with increased activity and expression of specific GRKs. This increase likely results in enhanced phosphorylation and desensitization of beta-ARs. These biochemical changes are consistent with observed aging physiology.
Subject(s)
Aging , Aorta/enzymology , Cyclic AMP-Dependent Protein Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism , Animals , Aorta/ultrastructure , Arrestins/analysis , Arrestins/metabolism , Cell Membrane/enzymology , Cyclic AMP-Dependent Protein Kinases/analysis , Cytoplasm/enzymology , G-Protein-Coupled Receptor Kinase 3 , G-Protein-Coupled Receptor Kinase 5 , Immunoblotting , Isoenzymes/analysis , Isoenzymes/metabolism , Male , Phosphorylation , Protein Serine-Threonine Kinases/analysis , Rats , Rats, Inbred F344 , Rhodopsin/metabolism , Vasodilation , beta-Adrenergic Receptor Kinases , beta-Arrestin 1 , beta-ArrestinsABSTRACT
beta-Adrenergic receptor (beta-AR)-mediated (cAMP-dependent) vasorelaxation declines with advancing age. It has been shown that angiotensin II (ANG II), a potent vasoconstrictor, enhances cAMP-mediated vasorelaxation. Therefore, we questioned whether ANG II could reverse age-related, impaired beta-AR-mediated vasorelaxation and cAMP production. Pretreatment of aortic rings from 6-wk-old or 6-mo-old male Fischer 344 rats with ANG II significantly enhanced vasorelaxation induced by isoproterenol (Iso), a beta-AR agonist, and forskolin, a direct activator of adenylyl cyclase, but not dibutyryl-cAMP or isobutylmethylxanthine. The ANG II effect was blocked by losartan but not PD-123319 and was not observed in the aortas from 12- and 24-mo-old animals. Iso-stimulated cAMP production in the aorta was enhanced in the presence of ANG II in the 6-wk-old and 6-mo-old age groups only. Results suggest ANG II cannot reverse the age-related impairment in beta-AR-dependent vasorelaxation. We conclude aging may affect a factor common to both ANG II-receptors and beta-AR signaling pathways or aging may impair cross-talk between these two receptor pathways.
Subject(s)
Aging/physiology , Angiotensin II/pharmacology , Aorta, Thoracic/physiology , Receptors, Angiotensin/metabolism , Vasoconstrictor Agents/pharmacology , Vasodilation/physiology , 1-Methyl-3-isobutylxanthine/pharmacology , Adrenergic beta-Agonists/pharmacology , Animals , Aorta, Thoracic/drug effects , Bucladesine/pharmacology , Colforsin/pharmacology , Cyclic AMP/metabolism , Imidazoles/pharmacology , In Vitro Techniques , Isoproterenol/pharmacology , Male , Phosphodiesterase Inhibitors/pharmacology , Pyridines/pharmacology , Rats , Rats, Inbred F344 , Receptor Cross-Talk/drug effects , Receptor Cross-Talk/physiology , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Vasodilation/drug effectsABSTRACT
Transplantable bone marrow stromal cells can be utilized for cell therapy of mesenchymal disorders. They can also be genetically engineered to express synthetic transgenes and subsequently serve as a platform for systemic delivery of therapeutic proteins in vivo. Inducible production of therapeutic proteins would markedly enhance the usefulness of stromal cells for cell therapy applications. We determined whether synthetic corticosteroid hormones can be used to tightly control transgene expression via the glucocorticoid response pathway in primary bone marrow stromal cells. This regulatory mechanism does not require the presence of potentially immunogenic prokaryotic or chimeric "Trans-activators." Further, synthetic corticosteroids are pharmaceutical agents that can be readily used in vivo. We designed a self-inactivating retroviral vector in which expression of the green fluorescent protein (GFP) reporter is controlled by a minimal synthetic promoter composed of five tandem glucocorticoid response elements upstream of a TATAA box. Vesicular stomatitis virus G-pseudotyped retroparticles were synthesized and utilized to transduce cultured cell lines and primary rat bone marrow stromal cells. We have shown that primary rat bone marrow stromal cells could be efficiently engineered with our GRE-containing retrovector, basal reporter expression was low in the absence of exogenous synthetic corticosteroids, and GFP expression was dexamethasone inducible and reversible. To summarize, this strategy allows dexamethasone-induced, "on-demand" transgene expression from transplantable genetically engineered bone marrow stromal cells.
Subject(s)
Bone Marrow Cells/physiology , Genetic Engineering/methods , Glucocorticoids/pharmacology , Retroviridae/genetics , Transgenes , Animals , Base Sequence , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Cells, Cultured , Dexamethasone/pharmacology , Gene Expression Regulation/drug effects , Genetic Vectors/genetics , Green Fluorescent Proteins , HeLa Cells , Humans , Luminescent Proteins/drug effects , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Male , Molecular Sequence Data , Rats , Rats, Inbred Lew , Response Elements/genetics , Stromal Cells/drug effects , Stromal Cells/physiologyABSTRACT
The interaction between the erbB tyrosine kinase receptors and their ligands plays an important role in tumor growth via the regulation of autocrine and paracrine loops. We report the effect of heregulin beta1, the ligand for erbB-3 and erbB-4 receptors, on the regulation of vascular endothelial growth factor (VEGF) expression, using a panel of breast and lung cancer cell lines with constitutive erbB-2 overexpression or engineered to stably overexpress the erbB-2 receptor. We demonstrate that heregulin beta1 induces VEGF secretion in most cancer cell lines, while no significant effect was observed in normal human mammary and bronchial primary cells. Overexpression of erbB-2 receptor results in induction of the basal level of VEGF and exposure to heregulin further enhances VEGF secretion. This is associated with increased VEGF mRNA expression. In contrast, VEGF induction is significantly decreased in a T47D cell line where erbB-2 is functionally inactivated. Conditioned media from heregulin-treated cancer cells, but not from normal cells, stimulates endothelial cell proliferation; this paracrine stimulation is inhibited by co-exposure to a specific VEGF neutralizing antibody. Furthermore, heregulin-mediated angiogenesis is observed in the in vivo CAM assay. This study reports the first evidence of VEGF regulation by heregulin in cancer cells. Oncogene (2000) 19, 3460 - 3469
Subject(s)
Endothelial Growth Factors/metabolism , ErbB Receptors/physiology , Lymphokines/metabolism , Neoplasm Proteins/physiology , Neovascularization, Pathologic , Neuregulin-1/physiology , Receptor, ErbB-2/physiology , Receptor, ErbB-3/physiology , Adenocarcinoma/pathology , Animals , Breast/cytology , Breast Neoplasms/pathology , Bronchi/cytology , Carcinoma, Non-Small-Cell Lung/pathology , Cell Division , Cells, Cultured/drug effects , Chick Embryo , Culture Media, Conditioned/pharmacology , Endothelial Growth Factors/antagonists & inhibitors , Endothelial Growth Factors/biosynthesis , Endothelial Growth Factors/genetics , ErbB Receptors/biosynthesis , ErbB Receptors/genetics , Female , Genes, erbB-2 , Humans , Lung Neoplasms/pathology , Lymphokines/antagonists & inhibitors , Lymphokines/biosynthesis , Lymphokines/genetics , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/metabolism , Neovascularization, Physiologic , Phosphorylation , Protein Processing, Post-Translational , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-3/biosynthesis , Receptor, ErbB-3/genetics , Receptor, ErbB-4 , Recombinant Fusion Proteins/physiology , Transfection , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Umbilical Veins/cytology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth FactorsABSTRACT
The antagonist activity of antiestrogens is due to the presence of a long carbon side chain at positions 7alpha or 11beta or equivalent on their steroid or steroid-like skeletons. These side chains establish hydrophobic interactions with amino acids of the estrogen receptor alpha (ERalpha) ligand binding domain. In addition, a hydrogen bond formed between amino acid Asp-351 and the tertiary amine present at the end of the side chain of partial antiestrogens is considered to be crucial for their antiestrogenicity. Here, we have investigated the role of Asp-351 in antiestrogen action in transiently transfected HeLa and MDA-MB-231 cells. Our results indicate that disruption of the negative charge at position 351 does not increase the agonist activity of partial antiestrogens and thus that the hydrogen bond with the antiestrogen side chain is not determinant in positioning the side chain in an antagonist position. The negative charge at position 351 was not required for transcriptional activity in the presence of hormone, but its presence was necessary for basal activity of the wild-type receptor and constitutive activities of mutants L536P and Y537A, suggesting a role of Asp-351 in stabilizing the active conformation of ERalpha. This stabilizing role of Asp-351 could be due to interaction of Asp-351 with the amide group of the peptide bond between Leu-539 and Leu-540 in helix 12 observed in the active conformation of the ERalpha ligand binding domain.
Subject(s)
Aspartic Acid/metabolism , Estrogen Receptor Modulators/pharmacology , Receptors, Estrogen/metabolism , Animals , Aspartic Acid/genetics , Binding Sites , COS Cells , Estradiol/pharmacology , Estrogen Receptor alpha , Gene Expression Regulation/drug effects , HeLa Cells , Humans , Mutation , Nuclear Receptor Coactivator 2 , Protein Binding , Protein Conformation , Receptors, Estrogen/antagonists & inhibitors , Receptors, Estrogen/genetics , Transcription Factors/metabolism , TransfectionABSTRACT
1. Decline in beta-adrenoceptor (beta-AR)-mediated function occurs with increasing age, as well as in multiple disease conditions. The mechanisms responsible for this decline include alterations in beta-AR itself, beta-AR coupling proteins, such as G-proteins, or other beta-AR-linked proteins, such as G-protein receptor kinases and/or phosphatases. 2. The present study examines the physiological effects of in vitro transfer of constitutively activated G alpha s (G alpha s-Q227L) to both cultured vascular smooth muscle cells (VSMC) and whole aortic tissue of 6-month-old (adult) animals via a replication-deficient Herpes simplex virus (HSV) vector. These studies were conducted to provide a model for future examination of the role of G alpha s in the age-related decline in beta-AR-mediated vasorelaxation. 3. Gene transfer was confirmed by western blotting for specific proteins. Aortic tissue infected with HSV-G alpha s-Q227L had reduced phenylephrine-induced contraction and enhanced isoproterenol-stimulated vasorelaxation. Infection of cultured VSMC with HSV-G alpha s-Q227L increased both basal- and isoproterenol-stimulated cAMP accumulation, whereas forskolin-stimulated cAMP production was unchanged. 4. These results implicate G alpha s as a target for further investigation in age-related changes in vascular reactivity and support the use of viral-mediated gene transfer as an effective tool to study adrenergic signal transduction and physiology in vascular tissue.
Subject(s)
Cyclic AMP/metabolism , GTP-Binding Proteins/metabolism , Gene Transfer Techniques , Muscle, Smooth, Vascular/metabolism , Vasodilation/physiology , Animals , Aorta/metabolism , Cells, Cultured , Cyclic AMP/genetics , GTP-Binding Proteins/genetics , Genetic Vectors/genetics , Male , Rats , Rats, Inbred F344 , Simplexvirus/genetics , Vasodilation/geneticsABSTRACT
Gait disorders are a frequent symptom of cervical spondylotic myelopathy (CSM). Twelve patients with CSM underwent gait analysis before and after decompressive surgery. They were assessed on a walkway and a treadmill and compared with a healthy matched control group. The following features were observed in the CSM group before surgery: significantly reduced gait velocity and step length (P<0. 05), prolonged double support, increased step width, and reduced ankle joint extension during treadmill walking. Knee and hip kinematics did not differ from controls. Two months after surgery, spatio-temporal parameters had moved towards normal values, velocity, step length and cadence had increased significantly, and there was reduction of step width during treadmill walking, indicating improved equilibrium. Gait analysis is an objective tool to document functional recovery after decompressive surgery in CSM.
Subject(s)
Gait/physiology , Spinal Cord Diseases/physiopathology , Cervical Vertebrae , Decompression, Surgical , Female , Humans , Male , Middle Aged , Spinal Cord Diseases/surgeryABSTRACT
Beta-adrenergic-mediated vasorelaxation declines with maturation and aging. Available data suggest that impaired stimulatory G-protein function could explain this deficit. We have previously found a loss of cholera toxin (CT)-stimulated adenosine diphosphate (ADP) ribosylation with age in rat aortic membrane preparations, without evidence for loss of the stimulatory alpha subunit of G protein (Gsalpha) by immunoblotting. The purpose of this investigation was to determine if cholera toxin-mediated vasorelaxation was also impaired with age. Aortic ring segments from 6 weeks, 6 months, 12 months, and 24 months old male F-344 rats were used. Contraction to KCl and phenylephrine was assessed along with relaxation to cholera toxin (azide-free), isoproterenol and forskolin. There were no age-related changes to KCl or phenylephrine contraction. There was a significant decrease with age in relaxation to isoproterenol. This loss with age was significantly greater with KCl-preconstricted vessels than phenylephrine-preconstricted vessels. There were no age-related changes in the relaxation to forskolin. There was a significant decrease with age in the maximal relaxation to cholera toxin as well as a rightward shift in the dose-response curve. Cholera toxin-stimulated adenosine 3', 5'-cyclic phosphate (cAMP) levels were measured and there was no increase in cAMP levels surrounding the time period associated with relaxation induced by cholera toxin. These data suggest that different preconstricting agents markedly affect the age-related changes in beta-adrenergic-mediated vasorelaxation. Furthermore, they suggest that the mechanism of cholera toxin-mediated vasorelaxation may not be mediated through increases in cAMP concentration.
Subject(s)
Aging/physiology , Aorta, Thoracic/drug effects , Cholera Toxin/pharmacology , Vasodilator Agents/pharmacology , Adenosine Diphosphate/metabolism , Adrenergic beta-Agonists/administration & dosage , Adrenergic beta-Agonists/pharmacology , Animals , Cholera Toxin/administration & dosage , Colforsin/administration & dosage , Colforsin/pharmacology , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , GTP-Binding Proteins/physiology , Isoproterenol/administration & dosage , Isoproterenol/pharmacology , Male , Phenylephrine/administration & dosage , Phenylephrine/pharmacology , Potassium Chloride/administration & dosage , Potassium Chloride/pharmacology , Rats , Rats, Inbred F344 , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/pharmacology , Vasodilator Agents/administration & dosageABSTRACT
Two studies are presented that investigate the assumptions that risk evaluation is based on subjective causal scenarios, and that the cognitive representation of global environmental risks is structured according to five causal levels: human attitudes, human activities, emissions or pollutions, environmental changes, and negative consequences. In study 1, 30 subjects listed in free-response format causes, consequences, and remedial measures for 14 environmental risks. Differences between predictive and diagnostic inferences were found: whereas subjects tend to assign immediate rather than mediated causes, they predominantly assign negative consequences for humans, irrespective of the length of the causal chain that leads to these consequences. In study 2, 41 subjects judged the overall similarity between 25 environmental risks. A multidimensional scaling analysis of these similarity judgments replicates the theoretically assumed five causal levels. Results of both studies support the assumptions that risk evaluation is based on implicit causal hypotheses and that the proposed five-level structure adequately describes the cognitive representation of environmental risks.
Subject(s)
Causality , Disasters , Environment , Perception , Adult , Aged , Cognition/physiology , Female , Humans , Male , Middle Aged , RiskABSTRACT
Estrogen receptor (ER)-positive human breast cancer cells are hormonally regulated and are inhibited by retinoids, whereas most ER-negative breast cancer cells are not. Here, we compared retinoid-induced transcriptional activation and growth inhibition in the ER-negative breast cancer cell line MDA-MB-231, stably transfected to express wild-type ER (S30), with that of the ER-positive MCF-7 line and the ER-negative parental line. Retinoids inhibited growth of the ER-expressing S30 clone but not of the parental MDA-MB-231 cells. Unlike a previously reported MDA-MD-231 subclone that was transfected to express a mutated ER (G400V), S30 did not express increased levels of retinoid receptor RNA or protein, nor was there increased binding activity to retinoid-responsive DNA elements. However, stable expression of ER increased retinoid activation of transcription of a retinoic acid (RA) response elements from the low level in MDA-MB-231 to approach the level of MCF-7. The restored growth inhibition and transcriptional regulation by RA were unaffected by treatment with ER agonists or antagonists. Transient expression of ER but not of other nuclear receptors in MDA-MB-231 cells also activated retinoid-induced transcription, showing that this response is specific to ER. Furthermore, the effect of exogenously expressed ER on retinoid response was much greater than that obtained by overexpression of RA receptor alpha and/or retinoid X receptor alpha. Finally, a panel of ER mutants showed that enhancement of retinoid-induced transcriptional activity was dependent on the integrity of the DNA binding domain.